Fexofenadine is NOT on the Beers List
Fexofenadine is not included in the American Geriatrics Society Beers Criteria® as a potentially inappropriate medication for older adults. This second-generation antihistamine is considered safe for use in the geriatric population.
Why Fexofenadine is Safe for Older Adults
The 2019 and 2023 AGS Beers Criteria 1, 2 list numerous medications to avoid in older adults, but fexofenadine is notably absent from all categories:
- Not listed among medications to avoid in most older adults (Table 2 of the criteria)
- Not listed among disease-specific medications to avoid (Tables 3 and 4)
- Not listed among medications requiring caution
- Not listed among problematic drug-drug interactions (Table 5)
- Not listed among medications requiring renal dose adjustment (Table 6)
Key Distinguishing Features
Non-Sedating Profile
Fexofenadine's exclusion from the Beers list is supported by its unique pharmacologic properties. The medication does not penetrate the blood-brain barrier, which eliminates the sedation and cognitive impairment concerns that plague first-generation antihistamines 3. PET scan studies demonstrate zero H1-receptor occupancy in the brain, and proportional impairment ratio (PIR) values consistently measure at 0, confirming no psychomotor or cognitive impairment even at doses higher than recommended 3.
Renal Considerations
While the FDA label notes that fexofenadine is substantially excreted by the kidney 4, it does not appear on the Beers Criteria list of medications requiring renal dose adjustment. The FDA recommends care in dose selection for elderly patients with decreased renal function and suggests monitoring renal function may be useful 4, but this is a general precaution rather than a specific contraindication.
Clinical Implications
Use fexofenadine as a first-line antihistamine in older adults for allergic rhinitis and chronic idiopathic urticaria. The standard adult dosing applies:
- Seasonal allergic rhinitis: 60 mg twice daily or 180 mg once daily
- Chronic idiopathic urticaria: 60 mg twice daily or 180 mg once daily
The medication's safety profile in older adults is well-established, with clinical studies showing no differences in adverse event profiles between geriatric and younger subjects 4.
Common Pitfall to Avoid
Do not confuse fexofenadine with first-generation antihistamines (like diphenhydramine or hydroxyzine), which ARE on the Beers list due to their strong anticholinergic properties and CNS effects. Fexofenadine represents a safer alternative specifically because it lacks these problematic properties 5.